CMA accuses hydrocortisone suppliers of anti-competitive behaviour

The UK Competition and Markets Authority (CMA) has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

CMA fines drugmakers £260m for 10,000% price hike

15 July 2021 The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

Big Pharma

Phenytoin judgment will help clarify unfair pricing tests, says UK’s CMA

12 March 2020 The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment.

Big Pharma

NHS to receive £8m from Aspen over anti-competitive practices

15 August 2019 Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.